Ea pharma corporation
WebEA Pharma Profile and History . EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the … WebFor the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the …
Ea pharma corporation
Did you know?
WebFeb 19, 2024 · 4. About EA Pharma Co., Ltd. EA Pharma, a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years’ history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business … WebJun 12, 2024 · For Japan market, EA Pharma concluded a license agreement for development and marketing of AJT240 with SANWA KAGAKU KENKYUSHO CO., LTD. …
WebJan 1, 2024 · EA Pharma has raised 2 rounds. Their latest funding was raised on Jan 1, 2024 from a Venture - Series Unknown round. EA Pharma is funded by 2 investors. HarbourVest Partners and Naxicap Partners are the most recent investors. EA Pharma has acquired Drasanvi on Aug 31, 2024. WebJul 18, 2024 · EA Pharma. Manufacturing · Japan · 28 Employees . EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 year's history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino …
WebMar 23, 2024 · About Nutra Pharma Corp. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization … WebDetails. Industries. Pharmaceutical. Headquarters Regions European Union (EU) Founded Date Apr 1, 2016. Operating Status Active. Last Funding Type Venture - Series …
WebApr 2, 2024 · The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where R1 to R5, e to h, D, and B represent those as described in the specification. Type: Grant. Filed: February 6, 2024. Date of Patent: February 18, 2024. Assignee: EA PHARMA CO., LTD.
WebSmall Molecule Pharma Explore With Us. Step into one of our M Lab™ Collaboration Centers where you can explore, learn, and collaborate. The Emprove® Program. Speed your way through the regulatory maze. Our Emprove® Program helps you meet the latest regulatory requirements for risk assessment. founders trace yellow wishWebSep 13, 2024 · About EA Pharma EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the … founders trade offWebJan 3, 2024 · EA Pharma Co., Ltd. GOOFICE® (elobixibat) is a first-in-class product candidate to treat chronic idiopathic constipation. The product is an inhibitor of the ileal bile acid transporter (IBAT) in the terminal ileum to increase secretion and motility in the large bowel without negatively affecting important functions in the small intestine ... disc crazy outdoor and moreWebEA Pharma 17,650 followers on LinkedIn. Votre partenaire santé au naturel : Innovation, Naturalité, Efficacité et Performance Les Laboratoires pharmaceutiques EA Pharma ont pour vocation d ... disc creatures best friendWebDec 27, 2024 · EA Pharma Company General Information. Description. Manufacturer of pharmaceuticals intended to provide medicines for unmet medical needs. The … founders towersWebEA Pharma, Mougins. 383 likes. Les Laboratoires EA Pharma développent, fabriquent et distribuent des médicaments et compléments disc creation softwareWebNov 23, 2024 · Most Recent Events. 14 Nov 2024 EA 4017 is still in phase I trials for Peripheral-nervous-system-diseases in Japan (Eisai pipeline, November 2024) 28 Sep 2024 No recent reports of development identified for phase-I development in Peripheral-nervous-system-diseases (In volunteers) in Japan (PO) 20 Jan 2024 EA 4017 is available for … founders trail dates